114 related articles for article (PubMed ID: 8913793)
1. In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68.
Mihara M; Urakawa K; Takagi N; Moriya Y; Takeda Y
Immunopharmacology; 1996 Oct; 35(1):41-6. PubMed ID: 8913793
[TBL] [Abstract][Full Text] [Related]
2. A novel non-polyglutamable anti-folate, MX-68, inhibits the induction of experimental autoimmune uveitis in rats.
Hiraoka M; Mihara M; Takeda Y; Miyasaka N
Exp Eye Res; 1998 Jul; 67(1):1-8. PubMed ID: 9702173
[TBL] [Abstract][Full Text] [Related]
3. Polyglutamation of a novel antifolate, MX-68, is not necessary for its anti-arthritic effect.
Urakawa K; Mihara M; Takagi N; Kawamura A; Akamatsu K; Takeda Y
Eur J Pharmacol; 2002 Jan; 435(2-3):237-44. PubMed ID: 11821032
[TBL] [Abstract][Full Text] [Related]
4. Polyglutamation of antifolates is not required for induction of extracellular release of adenosine or expression of their anti-inflammatory effects.
Urakawa K; Mihara M; Suzuki T; Kawamura A; Akamatsu K; Takeda Y; Kamatani N
Immunopharmacology; 2000 Jul; 48(2):137-44. PubMed ID: 10936511
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive properties of MX-68, a novel unpolyglutamatable antifolate.
Mihara M; Suzuki T; Kaneko E; Takagi N; Takeda Y
Biol Pharm Bull; 1997 Oct; 20(10):1071-5. PubMed ID: 9353567
[TBL] [Abstract][Full Text] [Related]
6. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.
Jolivet J; Chabner BA
J Clin Invest; 1983 Sep; 72(3):773-8. PubMed ID: 6193143
[TBL] [Abstract][Full Text] [Related]
7. A novel antifolate, MX-68, inhibits the development of autoimmune disease in MRL/lpr mice.
Mihara M; Takagi N; Urakawa K; Moriya Y; Takeda Y
Int Arch Allergy Immunol; 1997 Aug; 113(4):454-9. PubMed ID: 9250591
[TBL] [Abstract][Full Text] [Related]
8. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.
Goldman ID; Matherly LH
NCI Monogr; 1987; (5):17-26. PubMed ID: 2448654
[TBL] [Abstract][Full Text] [Related]
9. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate disposition, anti-folate activity and efficacy in the collagen-induced arthritis mouse model.
Singh RK; van Haandel L; Kiptoo P; Becker ML; Siahaan TJ; Funk RS
Eur J Pharmacol; 2019 Jun; 853():264-274. PubMed ID: 30951714
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate therapy in rheumatoid arthritis patients diminishes lectin-induced mononuclear cell proliferation.
Hine RJ; Everson MP; Hardin JM; Morgan SL; Alarcòn GS; Baggott JE; Koopman WJ; Krumdieck CL
Rheumatol Int; 1990; 10(4):165-9. PubMed ID: 2259842
[TBL] [Abstract][Full Text] [Related]
12. Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7).
Allegra CJ; Boarman D
Cancer Res; 1990 Jun; 50(12):3574-8. PubMed ID: 1692762
[TBL] [Abstract][Full Text] [Related]
13. Further studies on the pharmacologic effects of the 7-hydroxy catabolite of methotrexate in the L1210 murine leukemia cell.
Seither RL; Rape TJ; Goldman ID
Biochem Pharmacol; 1989 Mar; 38(5):815-22. PubMed ID: 2467676
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic resistance of cervical squamous cell carcinoma cell lines to methotrexate (MTX) as a result of decreased accumulation of intracellular MTX polyglutamates.
Barakat RR; Li WW; Lovelace C; Bertino JR
Gynecol Oncol; 1993 Oct; 51(1):54-60. PubMed ID: 7694891
[TBL] [Abstract][Full Text] [Related]
15. Preventive effect of a novel antifolate, MX-68, in murine systemic lupus erythematosus (SLE).
Mihara M; Takagi N; Urakawa K; Moriya Y; Takeda Y
Int J Immunopharmacol; 1997 Feb; 19(2):67-74. PubMed ID: 9278176
[TBL] [Abstract][Full Text] [Related]
16. Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-dianninopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats.
Han YH; Kato Y; Watanabe Y; Terao K; Asoh Y; Sugiyama Y
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):394-400. PubMed ID: 11259322
[TBL] [Abstract][Full Text] [Related]
17. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
Matherly LH; Angeles SM; McGuire JJ
Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells.
Whitehead VM
Cancer Res; 1977 Feb; 37(2):408-12. PubMed ID: 832265
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of folinic acid and glycine, adenosine, and thymidine as rescue agents in methotrexate-treated human cells in relation to the accumulation of methotrexate polyglutamates.
Rosenblatt DS; Whitehead VM; Matiaszuk NV; Pottier A; Vuchich MJ; Beaulieu D
Mol Pharmacol; 1982 May; 21(3):718-22. PubMed ID: 6180291
[TBL] [Abstract][Full Text] [Related]
20. Rescue effect of exogenous reduced folates on methotrexate polyglutamylation and dihydrofolate reductase activity in L1210 cells.
Balińska M
Acta Biochim Pol; 1988; 35(3):199-205. PubMed ID: 2469275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
